


T40Die orthopdischen Einlegesohlen Medicovi T40 bieten den ganzen Tag ber Komfort. Sie sind besonders geeignet bei Schmerzen in der Ferse (Fersensporn, Plantarfasziitis) sowie bei Schmerzen im vorderen Fubereich, in den Knien, den Hftgelenken und dem Rcken. Die Medicovi T40 Einlegesohlen sind auch fr Diabetiker geeignet, sie lindern Schmerzen und verhindern Fuverletzungen.
Quick Dispatch:
Your T40 orders ship within 1-2 business days.
Delivery Options:
- Standard: 3-7 business days
- Fast: 2-3 business days
- Express: 1-2 business days
Order Tracking:
You'll receive a tracking link by email once your T40 ships.
Need Help?
Questions about T40, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for T40 in your area.
Get Shipping Estimates
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
You may also like
4.4 ★★★★★
Based on 2015 reviews
Sort
Product Reviews
★★★★★ 3
It works
Size: Small-Medium, Color: Black/Anthracite/White
I bought this for the logo, I wish the back was easier to put on.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on May 13, 2026
★★★★★ 5
Perfect fit
Size: Small-Medium, Color: White/Anthracite/Black
Loved it!
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on April 20, 2026
★★★★★ 5
Cute visor!
Size: Small-Medium, Color: White/Anthracite/Black
Perfect hat. Exactly as described
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on April 2, 2026
★★★★★ 5
👍
Color: College Navy, Size: One Size
Ty. Very nice
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on June 7, 2026
★★★★★ 5
Nice visor
Color: White, Size: One Size
Visor fit well more like a unisex fit.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on March 1, 2026